National Healthcare Safety Network 2018 Baseline Neonatal Standardized Antimicrobial Administration Ratios.

TitleNational Healthcare Safety Network 2018 Baseline Neonatal Standardized Antimicrobial Administration Ratios.
Publication TypeJournal Article
Year of Publication2022
AuthorsO'Leary EN, Edwards JR, Srinivasan A, Neuhauser MM, Soe MM, Webb AK, Edwards EM, Horbar JD, Soll RF, Roberts J, Hicks LA, Wu H, Zayack D, Braun D, Cali S, Edwards WH, Flannery DD, Fleming-Dutra KE, Guzman-Cottrill JA, Kuzniewicz M, Lee GM, Newland J, Olson J, Puopolo KM, Rogers SP, Schulman J, Septimus E, Pollock DA
JournalHosp Pediatr
Date Published2022 Jan 24
ISSN2154-1671
Abstract

BACKGROUND: The microbiologic etiologies, clinical manifestations, and antimicrobial treatment of neonatal infections differ substantially from infections in adult and pediatric patient populations. In 2019, the Centers for Disease Control and Prevention developed neonatal-specific (Standardized Antimicrobial Administration Ratios SAARs), a set of risk-adjusted antimicrobial use metrics that hospitals participating in the National Healthcare Safety Network's (NHSN's) antimicrobial use surveillance can use in their antibiotic stewardship programs (ASPs).

METHODS: The Centers for Disease Control and Prevention, in collaboration with the Vermont Oxford Network, identified eligible patient care locations, defined SAAR agent categories, and implemented neonatal-specific NHSN Annual Hospital Survey questions to gather hospital-level data necessary for risk adjustment. SAAR predictive models were developed using 2018 data reported to NHSN from eligible neonatal units.

RESULTS: The 2018 baseline neonatal SAAR models were developed for 7 SAAR antimicrobial agent categories using data reported from 324 neonatal units in 304 unique hospitals. Final models were used to calculate predicted antimicrobial days, the SAAR denominator, for level II neonatal special care nurseries and level II/III, III, and IV NICUs.

CONCLUSIONS: NHSN's initial set of neonatal SAARs provides a way for hospital ASPs to assess whether antimicrobial agents in their facility are used at significantly higher or lower rates compared with a national baseline or whether an individual SAAR value is above or below a specific percentile on a given SAAR distribution, which can prompt investigations into prescribing practices and inform ASP interventions.

DOI10.1542/hpeds.2021-006253
Alternate JournalHosp Pediatr
PubMed ID35075483